The clinical significance of early airflow decline after myeloablative allogeneic hematopoietic SCT is uncertain. We performed a retrospective cohort analysis to determine if airflow decline by day 100 is associated with later development of transplant-related airflow obstruction (AFO) and increased mortality risk. Overall, 750 (40%) patients had airflow decline by day 100. Development of airflow decline by day 100 was associated with an increased risk for AFO at 1 year (relative risk 2.6, 95% confidence interval 2.1-3.1) but not with an increase in mortality risk (hazard ratio (HR) 0.86, P ¼ 0.05). However, patients with the fastest rate of decline between day 100 and 1 year (12.5% per year 724) had the highest mortality risk (HR 3.2, Po0.001). In conclusion, airflow measurements made on day 100 do not predict the rate of airflow decline between day 100 and 1 year, and therefore are not useful as a single measurement for determining mortality risk associated with development of AFO. Closer monitoring of the rate of airflow decline during the first year may facilitate the timely detection and treatment of early airflow decline and prevent the development of fixed AFO and increased mortality risk after hematopoietic stem cell transplant.
transplant; bronchiolitis obliterans
New-onset airflow obstruction (AFO) after myeloablative allogeneic hematopoietic stem cell transplant (HSCT) is the most common pulmonary complication among long-term survivors of HSCT, occurring in up to 26% of all allogeneic HSCT patients. 1 This clinical syndrome, also known as bronchiolitis obliterans, can have a devastating impact on mortality, with a 40% 10-year attributable mortality among patients with chronic graft-versus-host disease (GVHD). 1 Since there is a significant association between AFO and GVHD, [2] [3] [4] [5] [6] [7] [8] [9] immunosuppressive therapy has been considered appropriate for management of HSCT-related AFO. However, no beneficial effect has ever been documented. [10] [11] [12] [13] [14] [15] This may be partially because severe HSCT-related AFO is likely irreversible, such that immunosuppressive therapy may need to be instituted early in the clinical course to achieve any potential benefit. Unfortunately, the clinical significance of early airflow decline after myeloablative allogeneic HSCT is uncertain and, therefore, has not been considered as a potential indicator for the risk of developing HSCT-related AFO and its associated mortality risk.
A few small studies have considered some of the clinical implications of early decline in airflow after bone marrow transplantation (BMT). Schwarer et al 4 followed spirometric measurements closely during the first 2 years after BMT and found that significant decline of the 1-s forced expiratory volume (FEV 1 ) and forced vital capacity (FVC) preceded the onset of obstruction (FEV 1 /FVC ratio o0.75) by a median of 3 months in six out of 18 patients. Curtis et al 7 found significant reduction of the FEV 1 /FVC ratio and maximum mid-expiratory flow rate prior to the onset of AFO in five out of seven patients. These data, although never reproduced in a larger population, suggest that subclinical decline in airflow is likely to precede the onset of clinically recognized BMT-related AFO. Based upon these results, we hypothesized that early decline in airflow may be a useful indicator of an increased risk for the development of AFO and AFO-related mortality.
Methods

Patient population
All patients who received a single myeloablative allogeneic HSCT at the Fred Hutchinson Cancer Research Center between January 1, 1990 and December 31, 2000 were considered for this study. Patients were excluded if they had no baseline pulmonary function test (PFT), died without a day 100 PFT, or did not have a day 100 PFT.
Pulmonary function tests
PFTs were performed as described previously. 1 Published equations for children and adults were used to determine predicted values of FEV 1 and FVC. 16, 17 As part of usual protocol, pretransplant and day 100 (80720 days) PFTs were obtained regardless of the presence or absence of symptoms. After discharge from our institution by day 100, patients were encouraged to follow-up at the Fred Hutchinson Cancer Research Center 1 year (3657100 days) after transplant. Those who elected to return for follow-up at that time had a PFT as per protocol. Patients were considered to have airflow decline by day 100, the main predictor variable, if the annualized rate of percent predicted FEV 1 (pFEV 1 ) decline during the first 100 days (((baseline pFEV 1 Àday 100 pFEV 1 )/(day 100 PFT dateÀbaseline PFT date)) Â 365; day 100 PFT date ¼ the date at which day 100 PFTs were carried out; baseline PFT date ¼ the date at which baseline PFTs were carried out) was 45% per year and the day 100 FEV 1 /FVC ratio was o0.8. The presence of AFO at 1 year after HSCT is defined as an annualized rate of pFEV 1 decline 45% per year with the FEV 1 /FVC ratio o0.8 at 1 year. 1 For instance, over a 5-year period, a 30-year-old man who experiences a 5% annualized loss in pFEV 1 would lose more than 1254 ml in FEV 1 over 5 years, vs a loss of 122 ml secondary to normal aging.
17,18
Clinical variables
Clinical variables were collected prospectively as part of the usual clinical care and stored in a centralized data repository. Disease risk for all hematologic malignancies at transplant was classified as low, intermediate, or high according to disease type, extent of disease, and remission status. 19 Solid malignancies and nonhematologic diseases were classified as high risk. Allogeneic donor type categories were related matched, related mismatched, and unrelated. Donor match status was determined according to donor-recipient ABO compatibility and HLA-A, HLA-B, and DR status. Acute and chronic GVHD was graded based upon previously published clinical, histological, and laboratory criteria. 9, [20] [21] [22] Acute GVHD was assessed prior to day 100 and categorized as present (grade 2-4) or absent (grade 0-1). Chronic GVHD was categorized according to the presence or absence of clinical extensive chronic GVHD between days 100 and 365. Acute and chronic GVHD was then integrated and categorized as no acute or chronic GVHD, acute GVHD alone, de novo chronic GVHD (not preceded by acute GVHD), quiescent-onset chronic GVHD (preceded by acute GVHD that was followed by a period of quiescence), or progressive-onset chronic GVHD (immediately preceded by or concurrent with acute GVHD). Respiratory viral infection (RVI) with respiratory syncytial virus, parainfluenza virus, or influenza virus that was detected prior to the day 100 PFT was documented by either culture or direct fluorescent antibody staining of nasopharyngeal aspirate and/or bronchoalveolar lavage fluid. 23, 24 Statistical methods All statistical analyses were performed using STATA 6.0 (StataCorp, 1999). Two-sided P-values o0.05 were considered statistically significant. w 2 tests of independence were performed for univariate analyses. The presence of AFO by day 100 was analyzed in multivariable logistic and linear regression models. All models were adjusted for age at transplant, baseline FEV 1 /FVC ratio, GVHD category, history of RVI, and follow-up time, which were covariates previously determined to be significant risk factors for AFO. 1 Odds ratios and 95% confidence intervals (CIs) were corrected to relative risks (RRs), as described by Zhang and Yu. 25 Survival time for the entire cohort started from the day 100 PFT. Subanalysis was performed by grouping patients according to their day 100 and year 1 airflow status, with the survival time starting at the time of the PFT obtained at 1 year after transplant. An analysis of variance was performed for these groups to compare rates of pFEV 1 decline between day 100 and 1 year. The Kaplan-Meier method and log-rank test were used to estimate overall survival. 26 The Cox proportional hazard model was used to estimate mortality risk, adjusting for other potential causes of death after HSCT, with recurrent malignancy and chronic GVHD considered as time-dependent covariates when indicated.
Results
Patient characteristics
We identified 1892 patients who had baseline and day 100 PFTs (Figure 1 ). Of these, 977 patients did not have a PFT at 1 year. These patients were more likely to be between 20 and 40 years of age, had a higher disease risk, received higher total body irradiation dose, had slightly more progressive-onset chronic GVHD, and had a higher occurrence of disease relapse, most of which are known risk factors for the observed increase in overall mortality after day 100 ( Table 1 ). The distribution of pretransplant FEV 1 /FVC ratios and presence of significant airflow decline by day 100 did not differ significantly between the two groups (Table 1) . 
Development of airflow obstruction
Overall, 750 patients (40%) developed airflow decline by day 100. Univariate analysis suggested that age at transplant might confound the relationship between airflow decline by day 100 (w 2 ¼ 91.4, Po0.001) and the presence of AFO at 1 year (w 2 ¼ 8.5, P ¼ 0.01). History of RVI and gender match were not confounding factors because they were associated with significant airflow decline by day 100 (w 2 ¼ 10.4, P ¼ 0.001 and w 2 ¼ 10.02, P ¼ 0.02, respectively), but not at 1 year. There was also a significant association between airflow decline by day 100 and the presence of chronic GVHD (w 2 ¼ 5.2, P ¼ 0.02), but not acute GVHD or overall GVHD category. No association was found between airflow decline by day 100 and the remaining clinical variables.
Multivariable logistic regression analysis of all the patients who had PFTs at 1 year demonstrated that presence of airflow decline by day 100 was significantly associated with an increased risk of having AFO at 1 year after transplant (Table 2 ; RR 2.6, 95% CI 2.1-3.1). GVHD category and pretransplant FEV 1 /FVC ratio were also significantly associated with the presence of AFO at 1 year (Table 2 ). RVI and gender match categories were not associated with an increased risk for having AFO at 1 year in the multivariable analysis. The risk of having AFO at 1 year also differed slightly depending on the age at transplant; decline in airflow by day 100 was most strongly associated with the presence of AFO at 1 year in the 20-40 and older than 40 years of age groups (RR 2.9, 95% CI 2.1-3.8 and RR 2.5, 95% CI 1.9-3.1, respectively). Linear regression analysis demonstrated that significant decline in airflow by day 100 was associated with a faster annualized rate of pFEV 1 decline during the first year (overall, À3.2 vs À7.6% per year; stratified by age at transplant: 20-40, À3.7 vs À9.4% per year; 440, À3.4 vs À8.8% per year; Po0.001 for all comparisons).
Mortality risk
The airflow status at day 100 of all 1892 patients was analyzed for association with an increased risk for mortality after myeloablative allogeneic HSCT. After controlling for the most common causes of death after transplant (age at transplant, GVHD, disease risk at baseline, disease relapse, and RVI), patients who had airflow decline by day 100 were found to have a slightly decreased risk for mortality (hazard ratio (HR) 0.86, 95% CI 0.7-1.00, P ¼ 0.05). The mortality risks of the other covariates were consistent with a previous analysis. 1 Subanalysis was then conducted based upon the availability of PFTs at 1 year. As indicated in Table 1 , 977 patients (52%) did not have a PFT by 1 year after HSCT. There was again a slight decrease in risk for mortality among these patients (HR 0.8, 95% CI 0.7-0.98), similar to the entire cohort. The remaining 915 patients who had PFTs at 1 year were analyzed according to the presence of airflow decline at day 100 and 1 year after transplant: no/no 464 patients (51%), yes/no 181 patients (20%), no/yes 88 patients (9%), and yes/yes 182 patients (20%). There was significant variability in the rate of airflow decline calculated at day 100 (Table 3 ). This variability decreased significantly by 1 year. The no/yes group had the fastest median rate of airflow decline from day 100 to 1 year (no/no 1.5%/ year712.8; yes/no 8.1%/year718; no/yes À12.5%/ year724; yes/yes 3.4%/year715.7, Po0.001). Survival curves (Figure 2 ) demonstrate that patients in the no/yes group had the lowest survival rates at 3 years (29%), 5 years (31%), and 10 years (44%) after HSCT (Table 4) . Among patients with AFO at 1 year, patients who did not have early airflow decline also had the highest mortality risk (Table 5 ; no/yes, HR 3.2, 95% CI 2.0-5.2; yes/yes, HR 2.0, 95% CI 1.3-3.1). The mortality risk associated with the yes/no group was not significantly different from the reference group (no/no; Table 5 ). The difference between these two groups approached statistical significance (yes/ yes vs no/yes, P ¼ 0.06).
Discussion
New-onset AFO after HSCT has been recognized as an important predictor of mortality among patients who have received myeloablative allogeneic HSCT. 1, [27] [28] [29] [30] Some of these investigations have also documented a very close relationship between chronic GVHD and this syndrome, suggesting that HSCT-related AFO likely represents a pulmonary manifestation of chronic GVHD. [1] [2] [3] [4] [5] [6] [7] [8] [9] However, unlike chronic GVHD, the potential benefits of immunosuppressive therapy for HSCT-related AFO have never been documented or studied in a randomized fashion. This may be partly because current clinical practice is unable to identify patients with airflow decline early enough in their disease course. Since previous smaller descriptive studies have found that spirometric measurements tend to worsen prior to the onset of HSCT-related AFO, 4,7,31 we attempted There is a difference of the survival rates between these two subgroups that trended toward statistical significance (P ¼ 0.06). Presence of AFO at day 100 and year 1 is indicated by no/no, yes/no, no/yes, and yes/yes. Models for all patients adjusted for disease risk, presence of acute and/or chronic GVHD, and relapse of underlying disease.
to determine whether early changes in the pFEV 1 is associated with the presence of AFO 1 year after HSCT and estimate the effect of early airflow decline on survival.
The first finding of this study is the association between early airflow decline and the development of HSCT-related AFO. It is surprising that a modest 1.37% decline of the pFEV 1 during the first 100 days (equivalent to an annualized rate of 5% per year pFEV 1 decline) can increase the risk of having AFO at 1 year by 2.6 times, especially when there is such significant variability in the rate of airflow decline determined on day 100 (Table 3) . Unlike decline of total lung capacity and diffusion capacity during the first 100 days, which have been found to be reversible by 1 year after transplant, 31 early airflow decline during the first 100 days is not reversible by 1 year among a significant proportion of patients (20%). Irreversible airflow decline may represent early injury to small airways, which can initiate a bronchiolitis process that results in bronchial wall thickening and bronchiectasis that persist long after the initial insult. Such injury may be caused by events such as early RVIs, which have been documented by an earlier study 6 and later quantified by our previous analysis, 1 to increase the risk of developing HSCT-related AFO by 40%. Our data also indicate that some early airflow decline is reversible. This may reflect the overly sensitive nature of the criteria for early airflow decline, temporary effects of peritransplant events, host and/or donor biological differences, or reversal of early airflow decline due to immunosuppressive treatment effects. These data suggest that the day 100 PFT, when used without follow-up PFTs during the first year, is unlikely to be useful for finding patients with early airflow decline. Additional clinical data would be needed to confirm these hypotheses.
Our survival analysis reveals the most important finding that development of airflow decline by day 100 was not associated with an increase in mortality risk. In fact, the estimated HR was lower for the group of patients with early airflow decline. Although this unexpected finding may partially reflect an overly sensitive airflow criterion for AFO during the first 100 days, subgroup analysis revealed that even among patients who had AFO at 1 year (no/yes and yes/yes groups), the difference in mortality risk trended toward statistical significance. This correlates well with the fact that the no/yes group had the fastest rate of airflow decline between day 100 and 1 year (12.5%/year724). These results suggest that because the rate of airflow decline calculated on day 100 can vary significantly, it is the rate of decline between day 100 and 1 year after transplant that is likely to be more meaningful when trying to determine a patient's mortality risk, such that patients with the fastest rate of airflow decline during the first year after transplant are likely to experience the highest mortality risk. The rate of airflow decline during the first year is likely influenced by multiple factors that were unavailable for analysis, such as peritransplant events, genetic factors other than human leukocyte antigen matching, late respiratory infections, changes in immunosuppressive regimen, or differences in clinical management. If similar data are collected prospectively, with frequent monitoring of lung function during the first year after HSCT, it may be possible to determine the relationship between these clinical variables and development of early airflow decline. Frequent monitoring will also facilitate the timely detection of early airflow decline, prompting clinical investigations to rule out potential causes such as RVIs and/or exacerbation of chronic GVHD, and potentially affecting immunosuppressive taper decisions.
Our study is subject to some potential biases and limitations common to retrospective analyses. First, the analysis may be biased toward patients with chronic GVHD because they are more likely to return to our clinic for follow-up. Second, due to the nature of our database, we cannot comment on other nontransplant-related factors that might influence the rate of airflow decline, such as smoking history. Finally, our analysis was unable to consider all potential causes of death beyond 1 year after HSCT, the most common of which are bacterial and fungal infections. However, since infections tend to occur in the most immunosuppressed patients, we believe that this factor has been incorporated by the GVHD variables in the hazard model.
In conclusion, we have determined that although early airflow decline as early as day 100 after HSCT may be associated with development of HSCT-related AFO by 1 year, a single measurement of lung function on day 100 is not sufficient for determining the mortality risk that is associated with HSCT-related AFO. A more useful indicator of the mortality risk is the rate of airflow decline between day 100 and 1 year. Based upon these results, we have altered our clinical practice to consider the rate of airflow decline in our lung function tests. Airflow is monitored on a quarterly basis during the first year after transplant. When early airflow decline is suspected, monthly airflow measurements are performed to determine if the airflow decline improves, persists, or progresses. If the latter two are true without evidence of a respiratory infection and chronic GVHD is active, the patient is considered for immunosuppressive treatment options. We Table 5 Mortality risk among patients who had a PFT performed 1 year after myeloablative allogeneic HSCT believe that this approach to increase the vigilance for airflow decline during the first year after myeloablative allogeneic HSCT will permit the detection of HSCT-related airflow decline earlier and improve clinical management of HSCT-related AFO.
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